Celgene Cancer drug false claims suit verdict
Celgene Ordered to Pay $280 Million in Cancer Drug False Claims Suit
July 26, 2017
Drug manufacturer Celgene has agreed to pay $280 million to end a California False Claims Act suit that had accused it of promoting off-label uses for its bone cancer drugs Thalomid and Revlimid.
The suit alleged that Celgene had promoted Thalomid and Revlimid for the treatment of breast cancer and leukemia, despite the fact that the U.S. Food and Drug Administration (FDA) never approved either drug for those conditions. The two drugs have been approved only for the treatment of a bone marrow cancer called multiple myeloma.
Celgene had also been accused of paying doctors kickbacks to prescribe the drugs.
The settlement will be spread out among 28 states and the District of Columbia.
In settling the suit, Celgene insists that it has committed no wrongdoing, and is offering the $280 million to avoid the expense of protracted litigation.
The enormous, nationwide lawsuit was filed on the report of a whistleblower, who remains unidentified.
If you believe you have been prescribed medications under false pretenses, or if you feel that your doctor has been coerced by Big Pharma to prescribe a certain drug to you – you may be correct. This kind of thing happens more often than you may realize. Let the expert attorneys at TheLawFirm.com help you navigate the legal waters.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!